Intravitreal bevacizumab injection alone or combined with macular photocoagulation compared to macular photocoagulation as primary treatment of diabetic macular edema;Intravitrealna primena bevacizumaba sa ili bez laser-tretmana u poređenju sa laser-tretmanom kao primarnim načinom lečenja dijabetesnog edema makule

Vojnosanitetski Pregled

Volumn 72, Issue 10, 2015, Pages 876-882

  Jovanović, Sandra ^a   Čanadanović, Vladimir ^a   Sabo, Ana ^a   Grgić, Zorka ^a   Mitrović, Milena ^a   Rakić, Dušan ^a  

^a UNIVERSITY OF NOVI SAD   (Serbia)

Author keywords

Diabetic retinopathy; Light coagulation; Macular edema; Ophthalmologic surgical procedures; Treatment outcome; Vascular endothelial growth factors

Indexed keywords

BEVACIZUMAB; ANGIOGENESIS INHIBITOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG EFFICACY; EYE EXAMINATION; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; LASER COAGULATION; MACULAR THICKNESS; MAJOR CLINICAL STUDY; OPTICAL COHERENCE TOMOGRAPHY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TREATMENT RESPONSE; VISUAL ACUITY; CASE REPORT; CONVALESCENCE; FEMALE; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; PROCEDURES; SERBIA; TIME FACTOR; TREATMENT OUTCOME;

ADULT; AGED; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; COMBINED MODALITY THERAPY; DIABETIC RETINOPATHY; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; LASER COAGULATION; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECOVERY OF FUNCTION; SERBIA; TIME FACTORS; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84943157708     PISSN: 00428450     EISSN: 24060720     Source Type: Journal    
DOI: 10.2298/VSP140402074J     Document Type: Article

References (21)

1. Klein R. Retinopathy in a population-based study. Trans Am Ophthalmol Soc 1992; 90: 561-94.
2. Kempen JH, O'Colmain BJ, Leske MC, Haffner SM, Klein R, Moss SE, et al. The prevalence of diabeticretinopathy among adults in the United States. Arch Ophthalmol. 2004; 122(4): 552-63.
3. Orchard TJ, Dorman JS, Maser RE, Becker DJ, Drash AL, Ellis D, et al. Prevalence of complications in IDDM by sex and duration. Pittsburgh Epidemiology of Diabetes Complications Study II. Diabetes 1990; 39(9): 1116-24.
4. Girach A, Lund-Andersen H. Diabetic macular oedema: a clinical overview. Int J Clin Pract 2007; 61(1): 88-97.
5. Williams R, Airey M, Baxter H, Forrester J, Kennedy-Martin T, Girach A. Epidemiology of diabetic retinopathy and macular oedema: a systematic review. Eye 2004; 18(10): 963-83.
6. Gardner TW, Antonetti DA, Barber AJ, LaNoue KF, Levison SW. Diabetic retinopathy: more than meets the eye. Surv Ophthalmol 2002; 47(Suppl 2): S253-62.
7. Cai J, Boulton M. The pathogenesis of diabetic retinopathy: old concepts and new questions. Eye (Lond) 2002; 16(3): 242-60.
8. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 2002; 29(6 Suppl 16): 10-4.
9. Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci 2005; 109(3): 227-41.
10. Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK, Elman MJ, et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007; 114(10): 1860-7.
11. Fong DS, Strauber SF, Aiello LP, Beck RW, Callanan DG, Danis RP, et al. Writing Committee for the Diabetic Retinopathy Clinical Research Network. Comparison of the modified Early Treatment Diabetic Retinopathy Study and mild macular grid laser photocoagulation strategies for diabetic macular edema. Arch Ophthalmol 2007; 125(4): 469-80.
12. Wilkinson CP, Ferris FL, Klein RE, Lee PP, Agardh CD, Davis M, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 2003; 110(9): 1677-82.
13. Faghihi H, Esfahani MR, Harandi ZA, Madani SH. Intravitreal bevacizumab vs. combination of intravitreal bevacizumab plus macular photocoagulation in clinically significant diabetic macular edema: 6 months results of a randomized clinical trial. Iranian J Ophthalmol 2010; 22(1): 21-6.
14. Rajendram R, Fraser-Bell S, Kaines A, Michaelides M, Hamilton RD, Esposti SD, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3 Arch Ophthalmol 2012; 130(8): 972-9.
15. Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006; 26(9): 999-1005.
16. Kook D, Wolf A, Kreutzer T, Neubauer A, Strauss R, Ulbig M, et al. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema. Retina 2008; 28(8): 1053-60.
17. Mehta S, Blinder KJ, Shah GK, Kymes SM, Schlief SL, Grand MG. Intravitreal bevacizumab for the treatment of refractory diabetic macular edema. Ophthalmic Surg Lasers Imaging 2010; 41(3): 323-9.
18. Roh MI, Byeon SH, Kwon OW. Repeated intravitreal injection of bevacizumab for clinically significant diabetic macular edema. Retina 2008; 28(9): 1314-8.
19. Arevalo J, Fromow-Guerra J, Quiroz-Mercado H, Sanchez JG, Wu L, Maia M, et al. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology 2007; 114(4): 743-50.
20. Kumar A, Sinha S. Intravitreal bevacizumab (Avastin) treatment of diffuse diabetic macular edema in an Indian population. Indian J Ophthalmol 2007; 55(6): 451-5.
21. Lee SJ, Kim ET, Moon SY. Intravitreal bevacizumab alone versus combined with macular photocoagulation in diabetic macular edema. Korean J Ophthalmol 2011; 25(5): 299-304.